Controlled delivery of antisense oligodeoxynucleotide from cationically modified phosphorylcholine polymer films

Biomacromolecules

Volumn 7, Issue 3, 2006, Pages 784-791

  Zhang, ZhouQi ^a   Cao, XiChuan ^a   Zhao, XiuBo ^a   Withers, Sarah B ^a   Holt, Cathy M ^a   Lewis, Andrew L ^b   Lu, Jian R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; ELECTROPHORESIS; ELLIPSOMETRY; FLUORESCENCE;

ANTISENSE OLIGODEOXYNUCLEOTIDES (AS-ODNS); BIOCOMPATIBLE POLYMER; PHOSPHORYLCHOLINE POLYMER FILMS;

PLASTIC FILMS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; BIOMATERIAL; PHOSPHORYLCHOLINE; POLYMER;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ELLIPSOMETRY; ENCAPSULATION; FLUORESCENCE MICROSCOPY; GEL ELECTROPHORESIS; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; ULTRAVIOLET SPECTROPHOTOMETRY; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; BIOCOMPATIBLE MATERIALS; BIOPHYSICS; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR CONFORMATION; MUSCLE, SMOOTH; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLCHOLINE; POLYMERS; PROTO-ONCOGENE PROTEINS C-MYC; SWINE;

ANIMALIA;

EID: 33645526470     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm050840b     Document Type: Article

References (43)

1. Costa, M. A.; Simon, D. I. Molecular basis of restenosis and drug-eluting stents. Circulation 2005, 111, 2257-2273.
2. Klugherz, B. D.; Jones, P. L.; Cui, X.; Chen, W.; Meneveau, N. F.; DeFelice, S.; Connolly, J.; Wilensky, R. L.; Levy, R. J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol. 2000, 18, 1181-1184.
3. Walter, D. H.; Cejna, M.; Diaz-Sandoval, L.; Willis, S.; Kirkwood, L.; Stratford, P. W.; Tietz, A. B.; Kirchmair, R.; Silver, M.; Curry, C.; Wecker, A.; Yoon, Y. S.; Heidenreich, R.; Hanley, A.; Kearney, M.; Tio, F. O.; Kuenzler, P.; Isner, J. M.; Losordo, D. W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004, 110, 36-45.
4. Shi, Y.; Hutchinson, H. G.; Hall, D. J.; Zalewski, A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 1993, 88, 1190-1195.
5. Burgess, T. L.; Fisher, E. F.; Ross, S. L.; Bready, J. V.; Qian, Y. X.; Bayewitch, L. A.; Cohen, A. M.; Herrera, C. J.; Hu, S. S.; Kramer, T. B. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4051-4055.
6. Kipshidze, N.; Tsapenko, M.; Iversen, P.; Burger, D. Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opin. Biol. Ther. 2005, 5, 79-89.
7. Bennett, M. R.; Anglin, S.; McEwan, J. R.; Jagoe, R.; Newby, A. C.; Evan, G. I. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 1994, 93, 820-828.
8. Kipshidze, N. N.; Kim, H. S.; Iversen, P.; Yazdi, H. A.; Bhargava, B.; New, G.; Mehran, R.; Tio, F.; Haudenschild, C.; Dangas, G.; Stone, G. W.; Iyer, S.; Roubin, G. S.; Leon, M. B.; Moses, J. W. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J. Am. Coll. Cardiol. 2002, 39, 1686-1691.
9. Kipshidze, N. N.; Iversen, P.; Kim, H. S.; Yiazdi, H.; Dangas, G.; Seaborn, R.; New, G.; Tio, F.; Waksman, R.; Mehran, R.; Tsapenko, M.; Stone, G. W.; Roubin, G. S.; Iyer, S.; Leon, M. B.; Moses, J. W. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter. Cardiovasc. Interv. 2004, 61, 518-527.
10. Forte, A.; Galderisi, U.; De, F. M.; Gomez, M. F.; Esposito, S.; Santè, P.; Renzulli, A.; Agozzino, L.; Hellstrand, P.; Berrino, L.; Cipollaro, M.; Cotrufo, M.; Rossi, F., Cascino A. C-myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy. J. Vasc. Res. 2005, 42, 214-225.
11. Sharif, F.; Daly, K.; Crowley, J.; O'Brien, T. Current status of catheter- and stent-based gene therapy. Cardiovasc. Res. 2004, 64, 208-216.
12. Sousa, J. E.; Serruys, P. W.; Costa, M. A. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003, 107, 2274-2279.
13. Tepe, G.; Schmehl, J.; Wendel, H.; Schaffner, S.; Heller, S.; Gianotti, M.; Claussen, C.; Duda, S. Reduced thrombogenicity of nitinol stents - In vitro evaluation of different surface modifications and coatings. Biomaterials 2006, 27, 643-650.
14. Wang, D. A.; Feng, L. X.; Ji, J.; Sun, Y. H.; Zheng, X. X.; Elisseeff, J. H. Novel human endothelial cell-engineered polyurethane biomaterials for cardiovascular biomedical applications. J. Biomed. Mater. Res., Part A 2003, 65, 498-510.
15. Perlstein, I.; Connolly, J. M.; Cui, X.; Song, C.; Li, Q.; Jones, P. L.; Lu, Z.; DeFelice, S.; Klugherz, B.; Wilensky, R.; Levy, R. J. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther. 2003, 10, 1420-1428.
16. Banai, S.; Gertz, S. D.; Gavish, L.; Chorny, M.; Perez, L. S.; Lazarovichi, G.; Ianculuvich, M.; Hoffmann, M.; Orlowski, M.; Golomb, G.; Levitzki, A. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res. 2004, 64, 165-171.
17. Lewis, A. L.; Vick, T. A.; Collias, A. C.; Hughes, L. G.; Palmer, R. R.; Leppard, S. W.; Furze, J. D.; Taylor, A. S.; Stratford, P. W. Phosphorylcholine-based polymer coatings for stent drug delivery. J. Mater. Sci.: Mater. Med. 2001, 12, 865-870.
18. Lewis, A. L.; Tolhurst, L. A.; Stratford, P. W. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002, 23, 1697-1706.
19. Lewis, A. L. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Colloids Surf., B 2000, 18, 261-275.
20. Cumberland, D. C.; Gunn, J.; Malik, N.; Holt, C. M. Biomimicry 1: PC. Semin. Interv. Cardiol. 1998, 3, 149-150.
21. Malik, N.; Gunn, J.; Shepherd, L.; Crossman, D. C.; Cumberland, D. C.; Holt, C. M. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J. Invasive Cardiol. 2001, 13, 193-201.
22. Palmer, R. R.; Lewis, A. L.; Kirkwood, L. C.; Rose, S. F.; Lloyd, A. W.; Vick, T. A.; Stratford, P. W. Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 2004, 25, 4785-4796.
23. Putnam, D.; Gentry, C. A.; Pack, D. W.; Langer, R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1200-1205.
24. Hirosue, S.; Muller, B. G.; Mulligan, R. C.; Langer, R. Plasmid DNA encapsulation and release from solvent diffusion nanospheres. J. Controlled Release 2001, 70, 231-242.
25. Ravi Kumar, M. N.; Bakowsky, U.; Lehr, C. M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25, 1771-1777.
26. Breunig, M.; Lungwitz, U.; Klar, J.; Kurtz, A.; Blunk, T.; Goepferich, A. Polyplexes of polyethylenimine and per-N-methylated polyethylenimine-cytotoxicity and transfection efficiency. J. Nanosci. Nanotechnol. 2004, 4, 512-20.
27. Lewis, A. L.; Berwick, J.; Davies, M. C.; Roberts, C. J.; Wang, J. H.; Small, S.; Dunn, A.; O'Byrne, V.; Redman, R. P.; Jones, S. A. Synthesis and characterisation of cationically modified phospholipid polymers. Biomaterials 2004, 25, 3099-3108.
28. Murphy, E. F.; Keddie, J. L.; Lu, J. R.; Brewer, J.; Russell, J. The reduced adsorption of lysozyme at the phosphorylcholine incorporated polymer/aqueous solution interface studied by spectroscopic ellipsometry. Biomaterials 1999, 20, 1501-1511.
29. Tang, Y.; Lu, J. R.; Lewis, A. L.; Vick, T. A.; Stratford, P. W. Swelling of zwitterionic polymer films characterized by spectroscopic ellipsometry. Macromolecules 2001, 34, 8768-8776.
30. Azzam, R. M. A.; Bashara, N. M. Ellipsometry and Polarized Light; North-Holland: Amsterdam, 1977.
31. De Feitjer, J. A.; Nenjamins, J.; Veer, F. A. Ellipsometry as a tool to study the adsorption behaviour of synthetic and biopolymers at the air/water interface. Biopolymers 1978, 17, 1759.
32. Gunn, J.; Holt, C. M.; Francis, S. E.; Shepherd, L.; Grohmann, M.; Newman, C. M.; Crossman, D. C.; Cumberland, D. C. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ. Res. 1997, 80, 520-531.
33. Brazel, C. S.; Peppas, N. A. Mechanisms of solute and drug transport in relaxing, swellable, hydrophilic glassy polymers. Polymer 1999, 40, 3383-3398.
34. Stayton, P. S.; El-Sayed, M. E.; Murthy, N.; Bulmus, V.; Lackey, C.; Cheung, C.; Hoffman, A. S. "Smart" delivery systems for biomolecular therapeutics. Orthod. Craniofacial Res. 2005, 8, 219-225.
35. Jang, J. H.; Shea, L. D. Controllable delivery of nonviral DNA from porous scaffolds. J. Controlled Release 2003, 86, 157-168.
36. Zhang, J.; Chua, L. S.; Lynn, D. M. Multilayered thin films that sustain the release of functional DNA under physiological conditions. Langmuir 2004, 20, 8015-8121.
37. Hao, H.; Gabbiani, G.; Bochaton-Piallat, M. L. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1510-1520.
38. Edelman, E. R.; Simons, M.; Sirois, M. G.; Rosenberg, R. D. c-myc in vasculoproliferative disease. Circ. Res. 1995, 76, 176-182.
39. Lee, M.; Simon, A. D.; Stein, C. A.; Rabbani L. E. Antisense strategies to inhibit restenosis. Antisense Nucleic Acid Drug Dev. 1999, 9, 487-492.
40. Lu, J. R.; Murphy, E. F.; Su, T. J.; Lewis, A. L.; Stratford, P. W.; Satija, S. K. Reduced protein adsorption on the surface of a chemically grafted phospholipid monolayer. Langmuir 2001, 17, 3382-3389.
41. Tang, Y.; Su, T. J.; Armstrong, J.; Lu, J. R.; Lewis, A. L.; Vick, T. A.; Stratford, P. W.; Heenan, R. K.; Penfold, J. Interfacial structure of phosphorylcholine incorporated biocompatible polymer films. Macromolecules 2003, 36, 8440-8448.
42. Goreish, H. H.; Lewis, A. L.; Rose, S.; Lloyd, A. W. The effect of phosphorylcholine-coated materials on the inflammatory response and fibrous capsule formation: in vitro and in vivo observations. J. Biomed. Mater. Res., Part A 2004, 68, 1-9.
43. Rose, S. F.; Lewis, A. L.; Hanlon, G. W.; Lloyd, A. W. Biological responses to cationically charged phosphorylcholine-based materials in vitro. Biomaterials 2004, 25, 5125-5135.